Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYS6006 and Enlonstobart in Advanced Solid Tumors
NCT07622225Phase 2Not yet recruiting
- Sponsor
- CSPC Megalith Biopharmaceutical Co., Ltd.
- Start
- May 2026
- Primary completion
- Dec 2028
01
Overview
A Phase 2 trial of SYS6006 in solid tumor, sponsored by CSPC Megalith Biopharmaceutical Co., Ltd.. Planned start May 2026; status: not yet recruiting.
02
Drugs
SYS6006
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07622225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07622225.